poisar

Stocks · News reference

RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330

Benzinga Newsdesk

RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

COR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

    Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

    CORGMEDVCYTWST
  2. Brendan Coffey

    AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

    ABBVPFEMCKCAHCOR
  3. Na

    Is Generics Still a Quiet Profit Engine for Cardinal Health?

    Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.

    CAHMCKCOR
  4. Zacks.Com

    Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus

    Zacks highlights strong stock performance from its various rating systems and portfolios. Accelerant gained 53.7% after a Zacks Rank upgrade, while Shopify and Broadridge Financial gained 28.8% and 19.5% respectively over 12 weeks. General Mills climbed 22.9% as investors favored dividend stocks amid market volatility. The article demonstrates the effectiveness of Zacks' research methodologies across multiple portfolio strategies despite economic headwinds including sticky inflation and slowing consumer confidence.

    ARXMMMNSITZIMSHOP